NLRP3 and chronic kidney disease: Certainly, the pharmacological inhibition/mitigation of NLRP3 inflammasome activation should represent the better approach mainly because, despite the fact that the treatment of CKD has made great progress, drugs to protect the kidney and delay the progress of CKD are still limited.